No abstract available
MeSH terms
-
Activin Receptors, Type II / drug effects*
-
Activin Receptors, Type II / metabolism*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Biomarkers, Tumor / metabolism
-
Brentuximab Vedotin
-
Crizotinib
-
Disease-Free Survival
-
Humans
-
Immunoconjugates / therapeutic use
-
Ki-1 Antigen / metabolism*
-
Lymphoma, Large-Cell, Anaplastic / drug therapy*
-
Lymphoma, Large-Cell, Anaplastic / metabolism
-
Lymphoma, Large-Cell, Anaplastic / prevention & control*
-
Molecular Targeted Therapy / methods*
-
Prognosis
-
Protein Kinase Inhibitors
-
Pyrazoles / therapeutic use
-
Pyridines / therapeutic use
-
Secondary Prevention
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Immunoconjugates
-
Ki-1 Antigen
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyridines
-
Crizotinib
-
Brentuximab Vedotin
-
ACVRL1 protein, human
-
Activin Receptors, Type II